Biogen and Denali sign Parkinson’s drug deal worth $2bn
Biogen has entered into a binding agreement with Denali Therapeutics to jointly develop...
Focus:
-
![Ovid Angelini Angelman syndrome]()
Ovid and Angelini partner on treating Angelman syndrome in Europe
-
![Revitope Junshi]()
Revitope and Junshi collaborate on improved T-cell engager antibodies
-
![Novartis; Sangamo]()
Novartis partners with Sangamo on genomic therapies
-
![Roche; UCB]()
Roche and UCB partner to develop antibody therapy for Alzheimer’s
-
![licensing deals rare diseases]()
Licensing agreement deals decline in the rare diseases space, experts say
-
![Kiadis Sanofi NK cell therapy]()
Sanofi licenses Kiadis’s modified NK cell therapy for multiple myeloma
Most Read
- Ovid and Angelini partner on treating Angelman syndrome in Europe
- Revitope and Junshi collaborate on improved T-cell engager antibodies
- Sanofi licenses Kiadis’s modified NK cell therapy for multiple myeloma
- Access to Covid-19 vaccines: deep dive into Gavi’s COVAX AMC
- Investing in late-stage companies: Forbion closes Growth Fund at €185m
Latest Content
Biogen and Denali sign Parkinson’s drug deal worth $2bn
Biogen has entered into a binding agreement with Denali Therapeutics to jointly develop and commercialise therapeutics for Parkinson’s disease.
Ovid and Angelini partner on treating Angelman syndrome in Europe
US-based Ovid’s Angelman syndrome drug OV101 is currently in the late stages of a Phase III trial. With an approval on the horizon, Ovid has signed a partnership with Angelini to mirror existing US commercialisation preparations for the European market. What promise does OV101 have for at-need Angelman syndrome patients?
AstraZeneca signs first deal to supply Covid-19 vaccine in China
AstraZeneca has partnered with Shenzhen Kangtai Biological Products to manufacture its Covid-19 vaccine candidate in mainland China, marking its first deal to supply in the country.
Teva enters biosimilar commercialisation partnership with Alvotech
Israel-based Teva Pharmaceutical has formed an exclusive strategic collaboration with Alvotech to commercialise five biosimilar candidates in the US.
AstraZeneca to develop Redx’s drug for fibrotic diseases
AstraZeneca has entered into an agreement with UK-based biotechnology company Redx Pharma to licence a porcupine inhibitor, named RXC006, for fibrotic diseases.
Merck licences NASH drug efinopegdutide from Hanmi
Merck (MSD) has signed an exclusive licensing agreement with Hanmi Pharmaceutical to develop, manufacture and commercialise efinopegdutide (formerly HM12525A) to treat nonalcoholic steatohepatitis (NASH).
Revitope and Junshi collaborate on improved T-cell engager antibodies
Revitope and Junshi have teamed up to create next-generation T-cell engager cancer therapies; for the use of its TEAC platform, Revitope will be eligible for $160m in milestone payments. How do Revitope’s TEACs improve upon existing T-cell immunotherapy approaches?
Teva-Takeda joint venture divests certain assets in Japan to Nichi-Iko
A business joint venture (BV) of Teva Pharmaceutical and Takeda Pharmaceutical in Japan is set to divest the majority of its generic and operational assets to Nichi-Iko Pharmaceutical.
Novartis partners with Sangamo on genomic therapies
Novartis has signed an exclusive, global licensing collaboration agreement with Sangamo Therapeutics to develop and commercialise genomic therapies for neurodevelopmental disorders, including autism.
Intravacc and Celonic team up to develop Covid-19 vaccine
Intravacc has partnered with contract development and manufacturing organisation (CDMO) Celonic Group for the design, development and production of a Covid-19 vaccine.
Latest News
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.
Close
Close
Close
Go Top